<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2531">
  <stage>Registered</stage>
  <submitdate>12/10/2009</submitdate>
  <approvaldate>12/10/2009</approvaldate>
  <nctid>NCT00996151</nctid>
  <trial_identification>
    <studytitle>Testosterone MD-Lotion Residual Washing Study</studytitle>
    <scientifictitle>A Healthy Volunteer, Single Dose Phase I Trial to Determine the Amount of Testerone MD-Lotion 2% Remaining on the Axilla After Washing.</scientifictitle>
    <utrn />
    <trialacronym>MTE11</trialacronym>
    <secondaryid>MTE11</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hypergonadism</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Testosterone MD-Lotion

Treatment: drugs: Testosterone MD-Lotion
Single dose Testosterone MD-Lotion 2%

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The amount of Testerone MD-Lotion 2% remaining on the axilla after a single dose application in healthy males who undergo a post dose washing procedure.</outcome>
      <timepoint>March 2010</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The safety and tolerability of Testosterone MD-Lotion 2% following a single dose application. This will be performed by review of adverse events, EKG and assessment of laboratory parameters (haematology, biochemistry, urinalysis and hormone levels).</outcome>
      <timepoint>March 2010</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Healthy male subjects =18 and = 70 years</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Disqualifying concurrent condition or allergy/sensitivity to Testosterone MD-Lotion</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>10</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/02/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
    <hospital>QPharm Pty Ltd - Brisbane</hospital>
    <postcode>4006 - Brisbane</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Acrux DDS Pty Ltd</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study will evaluate the amount of Testosteron MD-Lotion 2% remaining on the axilla after
      a single dose application in healthy males who undergo a post dose washing procedure.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00996151</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Tina Soulis, PhD</name>
      <address>Acrux Pharma Pty Ltd</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>